Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectrum disorder (NMOSD). To evaluate the safety and efficacy of the CT103A, a self-...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Chuan, Tian, Dai-Shi, Zhou, Luo-Qi, Shang, Ke, Huang, Liang, Dong, Ming-Hao, You, Yun-Fan, Xiao, Jun, Xiong, Ying, Wang, Wen, Pang, Hao, Guo, Jing-Jing, Cai, Song-Bai, Wang, Di, Li, Chun-Rui, Zhang, Min, Bu, Bi-Tao, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810610/
https://www.ncbi.nlm.nih.gov/pubmed/36596762
http://dx.doi.org/10.1038/s41392-022-01278-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810610/
https://www.ncbi.nlm.nih.gov/pubmed/36596762
http://dx.doi.org/10.1038/s41392-022-01278-3

Ejemplares similares